ArticleCase reports in oncological medicine2025
A Rare Case of Akathisia After Removal of Subdural Hematoma During Treatment for Malignant Pleural Mesothelioma: Akathisia Induced by Brain Injury or Immune Checkpoint Inhibition.
Article in Case reports in oncological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A Rare Case of Akathisia After Removal of Subdural Hematoma During Treatment for Malignant Pleural Mesothelioma: Akathisia Induced by Brain Injury or Immune Checkpoint Inhibition.Case reports in oncological medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Akathisia is a movement disorder primarily caused by antipsychotic medications. Although extremely rare, cases caused by immune checkpoint inhibitors or traumatic brain injury have also been reported. We report on the case of an 82-year-old patient with malignant pleural mesothelioma who developed akathisia following subdural hematoma removal and achieved successful symptom control. Three months after receiving nivolumab and ipilimumab, the patient developed incomplete paralysis of the right side of the body. Examination and medical history revealed that a subdural hematoma was the cause of the movement abnormality. Following hematoma removal, the patient became unable to sit still. We suspected the condition as akathisia secondary to traumatic brain injury. Anticholinergic medication successfully controlled the symptoms, allowing treatment for mesothelioma to resume. Neurological immune-related adverse events associated with immune checkpoint inhibitors are often difficult to resolve completely and can lead to discontinuation of cancer treatment. We hope this case report underscores the importance of carefully evaluating the pathophysiology of neurological abnormalities arising during cancer treatment.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.